Organoids to Study Intestinal Nutrient Transport, Drug Uptake and Metabolism – Update to the Human Model and Expansion of Applications
暂无分享,去创建一个
H. Kessler | D. Haller | M. Ewers | G. Ceyhan | Tamara Zietek | F. Reichart | M. Weinmüller | E. Rath | I. E. Demir | P. Giesbertz | Elisabeth Urbauer | I. Demir
[1] V. Lauschke,et al. The past, present and future of intestinal in vitro cell systems for drug absorption studies. , 2020, Journal of pharmaceutical sciences.
[2] H. Clevers,et al. Human Organoids: Tools for Understanding Biology and Treating Diseases. , 2020, Annual review of pathology.
[3] L. Fricker. Proteasome Inhibitor Drugs. , 2020, Annual review of pharmacology and toxicology.
[4] L. Sibley,et al. Long-Term Culture Captures Injury-Repair Cycles of Colonic Stem Cells , 2019, Cell.
[5] G. Bánhegyi,et al. Species-Specific Glucose-6-Phosphatase Activity in the Small Intestine—Studies in Three Different Mammalian Models , 2019, International journal of molecular sciences.
[6] Ömer H. Yilmaz,et al. Gut Organoids: Mini-Tissues in Culture to Study Intestinal Physiology and Disease. , 2019, American journal of physiology. Cell physiology.
[7] K. Faber,et al. Corrigendum: Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases , 2019, Front. Immunol..
[8] M. Inoue,et al. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy , 2019, Cells.
[9] C. Kuo,et al. Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions , 2019, Cell reports.
[10] R. Damoiseaux,et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids , 2019, Communications Biology.
[11] Toshio Takahashi,et al. Organoids for Drug Discovery and Personalized Medicine. , 2019, Annual review of pharmacology and toxicology.
[12] K. S. Kim,et al. Microbiota-Derived Lactate Accelerates Intestinal Stem-Cell-Mediated Epithelial Development. , 2018, Cell host & microbe.
[13] H. Kessler,et al. Orally Active Peptides: Is There a Magic Bullet? , 2018, Angewandte Chemie.
[14] F. Kastrinos,et al. The Role of Genetics in Pancreatitis. , 2018, Gastrointestinal endoscopy clinics of North America.
[15] M. Magnuson,et al. Cytosolic phosphoenolpyruvate carboxykinase as a cataplerotic pathway in the small intestine. , 2018, American journal of physiology. Gastrointestinal and liver physiology.
[16] W. Langhans,et al. Enhancing enterocyte fatty acid oxidation in mice affects glycemic control depending on dietary fat , 2018, Scientific Reports.
[17] H. Kessler,et al. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway. , 2018, Molecular pharmaceutics.
[18] R. Lindeboom,et al. Integrative multi‐omics analysis of intestinal organoid differentiation , 2018, Molecular systems biology.
[19] J. Pippin,et al. Animal Research for Type 2 Diabetes Mellitus, Its Limited Translation for Clinical Benefit, and the Way Forward , 2018, Alternatives to laboratory animals : ATLA.
[20] E. Novellino,et al. Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3. , 2017, Angewandte Chemie.
[21] M. Schwaiger,et al. Exploring the Role of RGD-Recognizing Integrins in Cancer , 2017, Cancers.
[22] Flavio Ballante,et al. Limiting Assumptions in the Design of Peptidomimetics , 2017, Drug development research.
[23] V. M. D. Martins dos Santos,et al. Predicting the murine enterocyte metabolic response to diets that differ in lipid and carbohydrate composition , 2017, Scientific Reports.
[24] H. Clevers,et al. Organoid culture systems to study host–pathogen interactions , 2017, Current Opinion in Immunology.
[25] Horst Kessler,et al. Improving oral bioavailability of cyclic peptides by N-methylation. , 2017, Bioorganic & medicinal chemistry.
[26] Qing-Yu Zhang,et al. An update on the role of intestinal cytochrome P450 enzymes in drug disposition , 2016, Acta pharmaceutica Sinica. B.
[27] H. Walles,et al. Development of an Advanced Primary Human In Vitro Model of the Small Intestine. , 2016, Tissue engineering. Part C, Methods.
[28] Asher Mullard,et al. Parsing clinical success rates , 2016, Nature Reviews Drug Discovery.
[29] Tamara Zietek,et al. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1 , 2016, Front. Immunol..
[30] Olga Kovbasnjuk,et al. Human Enteroids as a Model of Upper Small Intestinal Ion Transport Physiology and Pathophysiology. , 2016, Gastroenterology.
[31] Amin Rostami-Hodjegan,et al. In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition , 2016, Drug Metabolism and Disposition.
[32] K. Ebert,et al. Fructose malabsorption , 2016, Molecular and Cellular Pediatrics.
[33] Dudley Lamming,et al. High fat diet enhances stemness and tumorigenicity of intestinal progenitors , 2016, Nature.
[34] H. Daniel,et al. Taste and move: glucose and peptide transporters in the gastrointestinal tract , 2015, Experimental physiology.
[35] H. Daniel,et al. Intestinal organoids for assessing nutrient transport, sensing and incretin secretion , 2015, Scientific Reports.
[36] Marion P G Koopmans,et al. Modeling rotavirus infection and antiviral therapy using primary intestinal organoids. , 2015, Antiviral research.
[37] K. Clément,et al. Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. , 2015, Cell metabolism.
[38] H. Daniel,et al. Intestinal nutrient sensing and blood glucose control , 2015, Current opinion in clinical nutrition and metabolic care.
[39] A. Kovar,et al. Metabolism and disposition of the αv‐integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans , 2015, Journal of clinical pharmacology.
[40] S. Kliewer,et al. Bile Acids as Hormones: The FXR-FGF15/19 Pathway , 2015, Digestive Diseases.
[41] E. Oki,et al. SPINK1 Status in Colorectal Cancer, Impact on Proliferation, and Role in Colitis-Associated Cancer , 2015, Molecular Cancer Research.
[42] Barbara M. Bakker,et al. Short-Chain Fatty Acids Protect Against High-Fat Diet–Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation , 2015, Diabetes.
[43] H. Clevers,et al. Targeting development of incretin-producing cells increases insulin secretion. , 2015, The Journal of clinical investigation.
[44] J. Segain,et al. Connecting metabolism to intestinal barrier function: The role of leptin , 2014, Tissue barriers.
[45] H. Miyoshi,et al. Development of an enhanced human gastrointestinal epithelial culture system to facilitate patient-based assays , 2014, Gut.
[46] M. Pangalos,et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework , 2014, Nature Reviews Drug Discovery.
[47] M. Leist,et al. Ex vivo culture of intestinal crypt organoids as a model system for assessing cell death induction in intestinal epithelial cells and enteropathy , 2014, Cell Death and Disease.
[48] Hans Clevers,et al. Adult Stem Cells in the Small Intestine Are Intrinsically Programmed with Their Location‐Specific Function , 2014, Stem cells.
[49] H. Daniel,et al. The Role of SGLT1 and GLUT2 in Intestinal Glucose Transport and Sensing , 2014, PloS one.
[50] M. Ghert,et al. Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.
[51] H. Daniel,et al. Peptide transporter isoforms are discriminated by the fluorophore‐conjugated dipeptides β‐Ala‐ and d‐Ala‐Lys‐N‐7‐amino‐4‐methylcoumarin‐3‐acetic acid , 2013, Physiological reports.
[52] R. Wanders,et al. Peroxisomes contribute to the acylcarnitine production when the carnitine shuttle is deficient. , 2013, Biochimica et biophysica acta.
[53] J. Arrowsmith,et al. Trial Watch: Phase II and Phase III attrition rates 2011–2012 , 2013, Nature Reviews Drug Discovery.
[54] B. Brodin,et al. Basolateral glycylsarcosine (Gly‐Sar) transport in Caco‐2 cell monolayers is pH dependent , 2013, The Journal of pharmacy and pharmacology.
[55] W. Langhans,et al. Diacylglycerol acyltransferase-1 inhibition enhances intestinal fatty acid oxidation and reduces energy intake in rats[S] , 2013, Journal of Lipid Research.
[56] A. Wali,et al. Microbial Regulation of Glucose Metabolism and Cell-Cycle Progression in Mammalian Colonocytes , 2012, PloS one.
[57] W. de Lau,et al. Peyer's Patch M Cells Derived from Lgr5+ Stem Cells Require SpiB and Are Induced by RankL in Cultured “Miniguts” , 2012, Molecular and Cellular Biology.
[58] Dudley Lamming,et al. mTORC1 in the Paneth cell niche couples intestinal stem cell function to calorie intake , 2012, Nature.
[59] J. Arrowsmith,et al. A decade of change , 2012, Nature Reviews Drug Discovery.
[60] J. Minna,et al. SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner. , 2011, Cancer research.
[61] H. Kessler,et al. The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. , 2011, Molecular pharmaceutics.
[62] W. Langhans,et al. Dietary fat sensing via fatty acid oxidation in enterocytes: possible role in the control of eating. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.
[63] Horst Kessler,et al. Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.
[64] Li Di,et al. Coexistence of passive and carrier-mediated processes in drug transport , 2010, Nature Reviews Drug Discovery.
[65] H. Daniel,et al. Gene ablation for PEPT1 in mice abolishes the effects of dipeptides on small intestinal fluid absorption, short-circuit current, and intracellular pH. , 2010, American journal of physiology. Gastrointestinal and liver physiology.
[66] G. Cresci,et al. Colonic Gene Expression in Conventional and Germ-Free Mice with a Focus on the Butyrate Receptor GPR109A and the Butyrate Transporter SLC5A8 , 2010, Journal of Gastrointestinal Surgery.
[67] B. Thorens,et al. Glucose transporters in the 21st Century. , 2010, American journal of physiology. Endocrinology and metabolism.
[68] Patrick J. Lindsey,et al. Butyrate-Induced Transcriptional Changes in Human Colonic Mucosa , 2009, PloS one.
[69] H. Clevers,et al. Single Lgr5 stem cells build cryptvillus structures in vitro without a mesenchymal niche , 2009, Nature.
[70] A. Leturque,et al. Sugar absorption in the intestine: the role of GLUT2. , 2008, Annual review of nutrition.
[71] Takahiko Nakagawa,et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. , 2007, The American journal of clinical nutrition.
[72] Ulf Norinder,et al. Exploring the role of different drug transport routes in permeability screening. , 2005, Journal of medicinal chemistry.
[73] A. Munnich,et al. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. , 2004, Molecular aspects of medicine.
[74] S. Korsmeyer,et al. Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix , 2004, Science.
[75] Marival Bermejo,et al. PAMPA--a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[76] H. Daniel,et al. PEPT1-Mediated Cefixime Uptake into Human Intestinal Epithelial Cells Is Increased by Ca2+ Channel Blockers , 2002, Antimicrobial Agents and Chemotherapy.
[77] U. Hopfer,et al. Mechanism of intestinal absorption and renal reabsorption of an orally active ace inhibitor: uptake and transport of fosinopril in cell cultures. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[78] K. Nair,et al. The effect of insulin on human small intestinal mucosal protein synthesis. , 2000, Gastroenterology.
[79] S. Grinstein,et al. Selective inhibition of the Na+/H+ exchanger type 3 activates CO2/H+-sensitive medullary neurones , 1999, Pflügers Archiv.
[80] D. Fleisher,et al. Transport of Pregabalin in Rat Intestine and Caco-2 Monolayers , 1999, Pharmaceutical Research.
[81] R. Santer,et al. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome , 1997, Nature Genetics.
[82] Shiyin Yee,et al. In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth , 1997, Pharmaceutical Research.
[83] Morton B. Brown,et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. , 1997, The Journal of clinical investigation.
[84] E. Wright,et al. Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption , 1996, Nature Genetics.
[85] V. Ganapathy,et al. Differential Recognition of β-Lactam Antibiotics by Intestinal and Renal Peptide Transporters, PEPT 1 and PEPT 2 (*) , 1995, The Journal of Biological Chemistry.
[86] Thomas Kolter,et al. Peptidomimetics for Receptor Ligands—Discovery, Development, and Medical Perspectives , 1993 .
[87] Thomas J. Raub,et al. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. , 1989, Gastroenterology.
[88] S. Gumina,et al. The Role of Genetics , 2017 .
[89] S. Shuto,et al. Conjugation of dipeptide to fluorescent dyes enhances its affinity for a dipeptide transporter (PEPT1) in human intestinal Caco-2 cells. , 1999, Bioconjugate chemistry.
[90] M. Pinto,et al. Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture , 1983 .